{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:33:47Z","timestamp":1793306027512,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.clgc.2023.01.005","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T23:08:50Z","timestamp":1674169730000},"page":"324-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6621-8251","authenticated-orcid":false,"given":"Fernando Sabino Marques","family":"Monteiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mollica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2023.01.005_bib0001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2023.01.005_bib0002","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.euf.2020.12.020","article-title":"A global trend analysis of kidney cancer incidence and mortality and their associations with smoking, alcohol consumption, and metabolic syndrome","volume":"8","author":"Huang","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2023.01.005_bib0003","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2023.01.005_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102207","article-title":"Adjuvant therapy in renal cell carcinoma: current knowledges and future perspectives","volume":"97","author":"Larroquette","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2023.01.005_bib0005","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.juro.2014.12.022","article-title":"Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience","volume":"193","author":"Bazzi","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0006","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clgc.2018.01.003","article-title":"Adjuvant therapies in nonmetastatic renal-cell carcinoma: a review of the literature","volume":"16","author":"Bandini","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"17_suppl","key":"10.1016\/j.clgc.2023.01.005_bib0007","doi-asserted-by":"crossref","first-page":"LBA4500","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA4500","article-title":"EVEREST: Everolimus for renal cancer ensuing surgical therapy\u2014a phase III study (SWOG S0931, NCT01120249)","volume":"40","author":"Ryan","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0008","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.01.005_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221108685","article-title":"Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review","volume":"14","author":"Lalani","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0010","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.01.005_bib0011","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2023.01.005_bib0012","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.2021.39.6_suppl.327","article-title":"Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study","volume":"39","author":"Plimack","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0013","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant Pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.01.005_bib0014","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2023.01.005_bib0015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1200\/JCO.2022.40.6_suppl.290","article-title":"Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: results from 30-month follow-up of KEYNOTE-564","volume":"40","author":"Choueiri","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0016","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2023.01.005_bib0017","doi-asserted-by":"crossref","first-page":"S1432","DOI":"10.1016\/j.annonc.2022.08.072","article-title":"LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial","volume":"33","author":"Allaf","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0018","doi-asserted-by":"crossref","first-page":"S1430","DOI":"10.1016\/j.annonc.2022.08.069","article-title":"LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial","volume":"33","author":"Motzer","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0019","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2023.01.005_bib0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/2046-4053-2-79","article-title":"The evolution of assessing bias in Cochrane systematic reviews of interventions: celebrating methodological contributions of the Cochrane Collaboration, 2","author":"Turner","year":"2013","journal-title":"Syst Rev"},{"key":"10.1016\/j.clgc.2023.01.005_bib0021","series-title":"Cochrane hand-book for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.clgc.2023.01.005_bib0022","unstructured":"NCCN Guidelines Kidney Cancer. 2023 [cited 2023 01\/02\/2023]; Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf."},{"key":"10.1016\/j.clgc.2023.01.005_bib0023","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.euo.2021.12.007","article-title":"Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy","volume":"5","author":"Laukhtina","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0024","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/PPO.0b013e3181b9c602","article-title":"Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials","volume":"15","author":"Buyse","year":"2009","journal-title":"Cancer J"},{"key":"10.1016\/j.clgc.2023.01.005_bib0025","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0026","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clgc.2023.01.005_bib0027","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/cncr.31154","article-title":"Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: a trial-level meta-analysis","volume":"124","author":"Harshman","year":"2018","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2023.01.005_bib0028","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2021.39.15_suppl.4581","article-title":"Disease-free survival as a predictor of overall survival in localized renal cell carcinoma (RCC) following first nephrectomy","volume":"39","author":"Haas","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0029","unstructured":"US Food & Drug Administration. Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment. 2022 [cited 2023 January 06, 2023]; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/renal-cell-carcinoma-developing-drugs-and-biologics-adjuvant-treatment."},{"key":"10.1016\/j.clgc.2023.01.005_bib0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molimm.2020.05.010","article-title":"Clinical relevance and prognostic significance of PD-1\/PD-Ls in non-metastatic bladder cancer: a role for PD-L2","volume":"124","author":"Ariafar","year":"2020","journal-title":"Mol Immunol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0031","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0032","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3389\/fimmu.2020.01088","article-title":"Looking for the optimal PD-1\/PD-L1 inhibitor in cancer treatment: a comparison in basic structure, function, and clinical practice","volume":"11","author":"Chen","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0033","doi-asserted-by":"crossref","first-page":"11472","DOI":"10.1038\/s41598-019-47910-1","article-title":"Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1\/PD-L1 signaling","volume":"9","author":"De Sousa Linhares","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2023.01.005_bib0034","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00280-022-04418-2","article-title":"Anti-drug antibodies in the current management of cancer","volume":"89","author":"Borreg\u00f3n","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0035","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1158\/1078-0432.CCR-19-2337","article-title":"Antidrug antibodies against immune checkpoint blockers: impairment of drug efficacy or indication of immune activation?","volume":"26","author":"Enrico","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2023.01.005_bib0036","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0037","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0038","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing Atezolizumab plus Bevacizumab vs Sunitinib in patients with previously untreated metastatic renal cell carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2023.01.005_bib0039","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1200\/JCO.2021.39.15_suppl.4576","article-title":"Efficacy of nivolumab\/ipilimumab in patients with initial or late progression with nivolumab: updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC)","volume":"39","author":"Grimm","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0040","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1200\/JCO.20.02295","article-title":"Optimized management of Nivolumab and Ipilimumab in advanced renal cell carcinoma: a response-based phase II study (OMNIVORE)","volume":"38","author":"McKay","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2023.01.005_bib0041","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1200\/JCO.2022.40.6_suppl.288","article-title":"Phase II study of nivolumab and salvage nivolumab\u202f+\u202fipilimumab in treatment-na\u00efve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): final report","volume":"40","author":"Atkins","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0042","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, phase II study of Pembrolizumab Monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0043","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jclinepi.2011.01.008","article-title":"Placebo effect studies are susceptible to response bias and to other types of biases","volume":"64","author":"Hr\u00f3bjartsson","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0044","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.04.044","article-title":"Informative censoring of surrogate end-point data in phase 3 oncology trials","volume":"153","author":"Gilboa","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2023.01.005_bib0045","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/cncr.34255","article-title":"Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: the potential impact of informative censoring","volume":"128","author":"Martini","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2023.01.005_bib0046","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40425-018-0319-9","article-title":"Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma","volume":"6","author":"Koshkin","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2023.01.005_bib0047","doi-asserted-by":"crossref","first-page":"e003844","DOI":"10.1136\/jitc-2021-003844","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 CheckMate 920 trial","volume":"10","author":"Tykodi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2023.01.005_bib0048","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.clgc.2019.11.012","article-title":"Clinical activity of ipilimumab plus nivolumab in patients with metastatic non-clear cell renal cell carcinoma","volume":"18","author":"Gupta","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2023.01.005_bib0049","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.euo.2020.01.001","article-title":"Synchronous versus metachronous metastatic disease: impact of time to metastasis on patient outcome\u2014results from the international metastatic renal cell carcinoma database consortium","volume":"3","author":"Donskov","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0050","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2018.05.002","article-title":"Adjuvant vascular endothelial growth factor\u2013targeted therapy in renal cell carcinoma: a systematic review and pooled analysis","volume":"74","author":"Sun","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0051","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/j.clgc.2018.12.011","article-title":"Adjuvant tyrosine kinase inhibitors in treatment of renal cell carcinoma: a meta-analysis of available clinical trials","volume":"17","author":"Massari","year":"2019","journal-title":"Clin Genitourinary Cancer"},{"key":"10.1016\/j.clgc.2023.01.005_bib0052","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.urolonc.2021.07.022","article-title":"Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis","volume":"39","author":"Laukhtina","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0053","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41467-021-21068-9","article-title":"Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma","volume":"12","author":"Bakouny","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.clgc.2023.01.005_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102374","article-title":"First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features","volume":"105","author":"Fontes-Sousa","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2023.01.005_bib0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MOU.0000000000000940","article-title":"Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis","volume":"32","author":"Quhal","year":"2022","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0056","doi-asserted-by":"crossref","first-page":"e001079","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.clgc.2023.01.005_bib0057","doi-asserted-by":"crossref","first-page":"S1430","DOI":"10.1016\/j.annonc.2022.08.070","article-title":"LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)","volume":"33","author":"Choueiri","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2023.01.005_bib0058","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/oncolo\/oyac140","article-title":"Clinical features, survival, and burden of toxicities in survivors more than one year after lung cancer immunotherapy","volume":"27","author":"Hsu","year":"2022","journal-title":"Oncologist"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2023.01.005_bib0059","doi-asserted-by":"crossref","first-page":"TPS5099","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5099","article-title":"A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914)","volume":"38","author":"Bex","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0060","doi-asserted-by":"crossref","first-page":"106482","DOI":"10.1016\/j.cct.2021.106482","article-title":"RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse","volume":"108","author":"Oza","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.clgc.2023.01.005_bib0061","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.annonc.2021.09.014","article-title":"ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma","volume":"32","author":"Powles","year":"2021","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2023.01.005_bib0062","doi-asserted-by":"crossref","first-page":"TPS4602","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4602","article-title":"LITESPARK-022: a phase 3 study of pembrolizumab\u202f+\u202fbelzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC)","volume":"40","author":"Choueiri","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.005_bib0063","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1158\/1078-0432.CCR-18-0323","article-title":"Validation of the 16-gene recurrence score in patients with locoregional, high-risk renal cell carcinoma from a phase III trial of adjuvant Sunitinib","volume":"24","author":"Rini","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2023.01.005_bib0064","article-title":"Application of machine learning models to predict recurrence after surgical resection of nonmetastatic renal cell carcinoma","author":"Khene","year":"2022","journal-title":"Eur Urol Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:37:16Z","timestamp":1761565036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323000253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1558767323000253"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.01.005","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}